Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation
At the current willingness-to-pay of 160,000 THB/QALY, no sequential IL-17 inhibitor was cost-effective compared to SoC. Secukinumab followed by ixekizumab or brodalumab then guselkumab (Sequence 1) may be the most appropriate option compared with other treatments.
Authors
- Bensachee Pattamadilok (ORCID: https://orcid.org/0000-0002-4871-2803)
- Leena Chularojanamontri (ORCID: https://orcid.org/0000-0001-6625-6445)
- Nopadon Noppakun (ORCID: https://orcid.org/0000-0003-2814-5845)
- Ratree Sawangjit (ORCID: https://orcid.org/0000-0002-6868-4336)
- Unchalee Permsuwan (ORCID: https://orcid.org/0000-0002-6909-2789)
- Piyameth Dilokthornsakul (ORCID: https://orcid.org/0000-0002-6981-1771)
- Natta Rajatanavin
Institutions
- Mahasarakham University (TH)
- Ministry of Public Health (TH)
- Siriraj Hospital (TH)
- Chulalongkorn University (TH)
- Mahidol University (TH)
- Institute of Dermatology (TH)
- Ramathibodi Hospital (TH)
- Chiang Mai University (TH)
- Naresuan University (TH)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1371/journal.pone.0307050
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer